Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes

Lee, Dong Hoon; Park, Kyung Ran; Kim, Seung Joon; Chung, Min Kyung; Lee, Yun Hee; Chang, Ji Hyun; Kang, Jin Hyoung; Hong, Sook Hee; Kim, Myung Sin; Kim, Yeon Sil

doi:10.1007/s13277-015-3776-5

Cited by 45 publications

(46 citation statements)

References 29 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High concentrations of LDH reflex anaerobic glycolytic metabolism in the tumor environment. [ 14 ] Lee et al [ 14 ] also found that, compared with the low metastatic score group, the patients in the high metastatic score group had significantly higher concentrations of serum LDH. Therefore, the concentrations of LDH reflect the extent of many tumors and could serve as a nonspecific marker, [ 14 ] which might be an underlying mechanism why high concentrations of LDH are associated with worse OS of lung cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…Although most studies concluded that higher pretreatment LDH concentration was associated with worse OS in patients with lung cancer, [ 10 – 14 , 21 – 25 ] some studies did not come to this conclusion. [ 4 , 15 , 16 , 20 ] LDH is increased not only in cancer patients but also in other diseases, for example, infections, heart failure, acute pancreatitis and anemia, and so on.…”

Section: Discussionmentioning

confidence: 99%

“…Some studies demonstrated that higher LDH was associated with poorer prognosis in lung cancer patients. [ 10 – 14 ] However, some researchers found that this association was not significant. [ 4 , 15 , 16 ] Due to the controversy, we aimed to perform a meta-analysis to systematically evaluate the prognostic role of LDH in patients with lung cancer.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Higher pretreatment lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer

Deng¹,

Yan-fa

Zhou³

et al. 2018

Medicine

View full text Add to dashboard Cite

Background:The aim of this study was to systematically evaluate the prognostic role of pretreatment lactate dehydrogenase (LDH) concentration for survival in patients with lung cancer through performing a meta-analysis.Methods:PubMed, EMBASE, Cochrane Library, Web of Science, and China National Knowledge Infrastructure were searched for potentially relevant literature. The study and patients’ characteristics were extracted. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were pooled to estimate the prognostic role of LDH in patients with lung cancer.Results:Fourteen studies with 4084 patients were included. Higher pretreatment LDH concentration was significantly associated with an increased risk of overall mortality in patients with lung cancer (HR = 1.49, 95% CI, 1.38–1.59). Subgroup analysis of studies also resulted in a significantly increased risk of mortality in patients with small cell lung cancer (SCLC, HR = 1.54, 95% CI, 1.43–1.67) or nonsmall cell lung cancer (NSCLC, HR = 1.25, 95% CI, 1.06–1.46), with high pretreatment LDH concentration. No significant between-study heterogeneity was observed (I2 = 12.0%, P = .321). No significant publication bias was found (P = .352) in the meta-analysis.Conclusion:The results suggested that higher pretreatment LDH concentration was associated with worse overall survival in patients with lung cancer. The findings may assist future research on anticancer therapy by targeting LDH and help predict prognosis in lung cancer patients. However, high-quality studies are required to further research and support these associations. Moreover, confounding factors such as patient ethnicity and tumor type should be considered in future studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Higher pretreatment lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer

Deng¹,

Yan-fa

Zhou³

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

“…An enhanced serum LDH level has been reported as a poor prognostic factor in patients with various malignant tumors, including breast cancer, T-cell lymphoma [ 20 ], pancreatic carcinoma [ 21 ], and renal cell carcinoma [ 22 ]. The LDH levels were significantly higher in metastatic stage IV lung cancer patients who were enrolled in a study of 329 lung cancer patients [ 23 ]. In addition, by analyzing 309 advanced-stage NSCLC patients treated with erlotinib, it was found that the change in LDH level during the first month was a surrogate marker for the efficacy of erlotinib in advanced NSCLC [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Lactate dehydrogenase and creatine kinase as poor prognostic factors in lung cancer: A retrospective observational study

Liu

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

PurposeCirculating molecules play important roles in lung cancer diagnosis. In addition, plasma lactate dehydrogenase (LDH) and creatine kinase (CK) have been shown to be closely related to tumor progression in breast cancer, prostate cancer, and colonel cancer. However, the relationships between LDH and CK levels with metastasis occurrence and the survival status of lung cancer patients remain unclear.Experimental designA total of 1142 lung cancer patients were enrolled in this study and were separated into negative or positive groups, according to the plasma levels of CK or LDH. Patients in both groups were assessed for clinical characteristics, metastasis occurrence, and survival status. The Cox regression model was then introduced to confirm whether CK and LDH could act as independent factors for predicting a poor prognosis.ResultsThe results indicated that CK had a close relationship with bone (p < 0.05) and lymph node (p < 0.05) metastases. In addition, LDH was strongly related with bone (p < 0.05), adrenal gland (p < 0.05), and lymph node (p < 0.05) metastases. CK and LDH were also correlated with the survival status of the lung cancer patients (all p < 0.001). According to specific histological classification analysis, it was found that CK was closely related to the survival status of adenocarcinoma (ADC) and squamous cell carcinoma (SCC) patients, while LDH was only correlated with that of ADC patients. Cox regression analysis confirmed that CK and LDH could act as independent factors for predicting a poor prognosis in ADC but not SCC patients.ConclusionsFor the first time, our study confirmed the role of CK in metastasis occurrence and the survival status of lung cancer patients. In addition, it also demonstrated that CK and LDH could be used as independent factors to predict a poor prognosis in ADC patients. The identification of CK and LDH will play important roles in lung cancer diagnosis and poor outcome prediction in the future.

show abstract

“…[5] Although several prognostic biomarkers including maximum standardized uptake value (SUVmax) obtained by 18-fluoro-2-deoxyglucose positron emission tomography/computed tomography, [6] epidermal growth factor receptor (EGFR) status, [7] programmed death-ligand 1, [8] and serum lactate dehydrogenase in advanced NSCLC [9] have been suggested, currently there is no validated biomarker for patients with advanced NSCLC to predict their survival outcome.…”

Section: Introductionmentioning

confidence: 99%

Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy

Koh¹,

Lee

2017

Medicine

View full text Add to dashboard Cite

Recent studies have indicated that the C-reactive protein (CRP)/albumin (CRP/Alb) ratio is associated with clinical outcomes in patients with various carcinomas. However, no studies have explored the association between the ratio of CRP/Alb and clinical outcome of inoperable patients with nonsmall cell lung cancers (NSCLCs). We examined the prognostic impact of CRP/Alb ratio on 165 stage IV NSCLC receiving palliative chemotherapy. The optimal cutoff level of CRP/Alb ratio was set at 0.195. The median follow-up time was 9 months (range, 1–74 months). On univariate analysis, high CRP/Alb ratio (≥0.195) was correlated (P < .001) with poorer overall survival (OS). Subgroup analysis of adenocarcinoma showed that CRP/Alb ratio was significantly (P < .001) associated with OS. Multivariate analysis showed that CRP/Alb ratio was an independent prognostic factor for OS (hazard ratio: 2.227, P = .001). Subgroup analysis revealed that the CRP/Alb ratio had a significant (P = .001) prognostic impact on adenocarcinoma patients receiving platinum chemotherapy. Elevated CRP/Alb ratio was significantly associated with male gender (P = .002) and smoking history (P = .009). The results of this study suggest that the CRP/Alb ratio might be used as a simple, inexpensive, and independent prognostic factor for OS of patients with advanced lung adenocarcinomas receiving platinum chemotherapy.

show abstract

Serum lactate dehydrogenase levels at presentation in stage IV non-small cell lung cancer: predictive value of metastases and relation to survival outcomes

Cited by 45 publications

References 29 publications

Higher pretreatment lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer

Higher pretreatment lactate dehydrogenase concentration predicts worse overall survival in patients with lung cancer

Lactate dehydrogenase and creatine kinase as poor prognostic factors in lung cancer: A retrospective observational study

Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy

Contact Info

Product

Resources

About